Compare CRDO & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDO | TAK |
|---|---|---|
| Founded | 2008 | 1781 |
| Country | Cayman Islands | Japan |
| Employees | N/A | 47029 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.7B | 55.1B |
| IPO Year | 2022 | N/A |
| Metric | CRDO | TAK |
|---|---|---|
| Price | $218.67 | $16.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $179.62 | N/A |
| AVG Volume (30 Days) | ★ 5.7M | 3.7M |
| Earning Date | 06-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.24% |
| EPS Growth | ★ 765.52 | N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $1,335,116,000.00 | N/A |
| Revenue This Year | $210.92 | $0.16 |
| Revenue Next Year | $57.22 | $1.22 |
| P/E Ratio | $82.47 | ★ $41.25 |
| Revenue Growth | ★ 205.68 | N/A |
| 52 Week Low | $86.49 | $12.99 |
| 52 Week High | $308.67 | $18.90 |
| Indicator | CRDO | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 50.92 |
| Support Level | $192.93 | $16.21 |
| Resistance Level | $241.14 | $17.02 |
| Average True Range (ATR) | 17.84 | 0.28 |
| MACD | -2.07 | -0.02 |
| Stochastic Oscillator | 54.46 | 39.17 |
Credo Technology Group Holding Ltd provides connectivity solutions for AI-driven applications, cloud computing, and hyperscale networks. Its high-speed copper and optical interconnect products support data infrastructure demands. The Company's product portfolio includes ZeroFlap (ZF) Active Electrical Cables (AECs), ZF optical transceivers, OmniConnect memory solutions, and retimers and DSPs for optical and copper Ethernet and PCIe, leveraging the PILOT diagnostic and analytics software platform. Its products are based on Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies and include integrated circuits (ICs), Active Electrical Cables (AECs), SerDes Chiplets, and SerDes IP licensing solutions. The United States generates the maximum revenue.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.